Category: Pharmaceuticals - Page 2
Government Response to Drug Shortages: Federal Actions and Policy Shifts in 2025-2026
Federal actions to combat drug shortages in 2025-2026 focus on stockpiling active ingredients and regulatory tweaks, but fail to fix the root causes: manufacturing concentration, low profit margins, and weak reporting. Real solutions require economic reform, not just emergency reserves.
Switching Between Generic Medications: What You Need to Know
Switching between different generic medications can be safe-or risky, depending on the drug. Learn which medications require caution, how to spot changes, and what to ask your doctor and pharmacist to stay protected.
Effective Patent Life: Why Market Exclusivity in Pharmaceuticals Is Shorter Than You Think
Effective patent life is often just 10-13 years for new drugs, not the full 20 years. Learn why patents expire faster than you think, how companies stretch exclusivity, and what it means for drug prices and patient access.
FDA Proposed PMI Changes: What Patients and Pharmacies Need to Know
The FDA is introducing a new standardized Patient Medication Information (PMI) format for all outpatient prescriptions, replacing inconsistent Medication Guides with a single-page, easy-to-read handout to reduce errors and improve safety.
Current Drug Shortages: Which Medications Are Scarce Today in 2026
As of early 2026, over 260 essential medications remain in short supply across the U.S., including chemotherapy drugs, IV fluids, and antibiotics. Learn which drugs are hardest to find, why, and what you can do.
GLP-1 Agonists for Weight Loss: Real Benefits and Common Side Effects
GLP-1 agonists like Wegovy and Zepbound can help people lose 15-20% of body weight, but come with nausea, high costs, and require long-term use. Learn how they work, their real side effects, and what to expect.
FDA's 180-Day Exclusivity: How First Generic Applicants Gain Market Advantage
FDA's 180-day exclusivity gives the first generic drug applicant a legal edge to launch without competition-but loopholes let companies delay entry. Here's how it works, who benefits, and why reform is urgent.
Renal Dosing of Antibiotics: How to Avoid Toxicity in Kidney Disease
Proper antibiotic dosing in kidney disease prevents toxicity and treatment failure. Learn how creatinine clearance guides dosing, which antibiotics need adjustments, and why acute vs. chronic kidney injury changes everything.
FDA Sentinel Initiative: How Big Data Detects Drug Safety Issues
The FDA Sentinel Initiative uses big data from millions of patient records to detect drug safety issues in real time, replacing outdated reporting systems with active surveillance powered by AI and real-world evidence.
ACE Inhibitors and ARBs: What You Need to Know About Interactions and Cross-Reactivity
ACE inhibitors and ARBs treat high blood pressure and kidney disease but shouldn't be combined. Learn why mixing them raises risks of kidney failure and high potassium-and what safer alternatives exist.